Vir Biotechnology (VIR) Financials

$5.21 +0.11 (+2.16%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.12 -0.09 (-1.63%)

As of 06/18/2025 07:56 PM Eastern

Annual Income Statements for Vir Biotechnology

This table shows Vir Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-70	-116	-175	-299	529	516	-615	-522
Consolidated Net Income / (Loss)	-70	-116	-175	-299	529	516	-615	-522
Net Income / (Loss) Continuing Operations	-70	-116	-175	-299	529	516	-615	-522
Total Pre-Tax Income	-81	-116	-175	-299	550	754	-628	-523
Total Operating Income	-81	-119	-178	-297	421	833	-684	-587
Total Gross Profit	2.71	11	8.09	76	1,030	1,469	83	73
Total Revenue	2.71	11	8.09	76	1,095	1,616	86	74
Operating Revenue	2.71	11	8.09	76	1,095	1,616	86	74
Total Cost of Revenue	0.00	0.00	0.00	0.00	66	146	2.77	0.85
Operating Cost of Revenue	-	-	0.00	0.00	66	146	2.77	0.85
Total Operating Expenses	84	129	186	373	609	636	768	661
Selling, General & Admin Expense	22	29	38	71	161	162	174	119
Research & Development Expense	63	100	148	302	448	475	580	506
Restructuring Charge	-	-	-	-	-	0.00	14	35
Total Other Income / (Expense), net	0.72	2.33	3.45	-1.63	129	-79	56	64
Interest & Investment Income	0.64	-	-	-	0.44	28	87	72
Other Income / (Expense), net	0.08	-0.21	-5.06	-4.47	129	-107	-31	-7.75
Income Tax Expense	-11	-0.48	0.15	0.05	21	238	-13	-1.15
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	0.00	0.00	-0.06	0.00
Basic Earnings per Share	($32.45)	($15.12)	($5.76)	($2.51)	$4.07	$3.89	($4.59)	($3.83)
Weighted Average Basic Shares Outstanding	2.15M	7.67M	30.35M	119.16M	129.88M	132.61M	134.13M	136.25M
Diluted Earnings per Share	($32.45)	($15.12)	($5.76)	($2.51)	$3.96	$3.83	($4.59)	($3.83)
Weighted Average Diluted Shares Outstanding	2.15M	7.67M	30.35M	119.16M	133.44M	134.81M	134.13M	136.25M
Weighted Average Basic & Diluted Shares Outstanding	2.15M	7.67M	30.35M	119.16M	132.30M	133.53M	135.03M	137.14M

This table shows Vir Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	175	-102	-141	-195	-163	-116	-65	-138	-214	-105	-121
Consolidated Net Income / (Loss)	175	-102	-141	-195	-163	-116	-65	-138	-214	-105	-121
Net Income / (Loss) Continuing Operations	175	-102	-141	-195	-163	-116	-65	-138	-214	-105	-121
Total Pre-Tax Income	218	-152	-143	-198	-167	-121	-65	-140	-214	-105	-121
Total Operating Income	195	-151	-143	-215	-187	-139	-80	-159	-231	-117	-140
Total Gross Profit	352	43	61	3.78	2.60	16	56	3.02	2.33	12	3.03
Total Revenue	375	49	63	3.80	2.64	17	56	3.08	2.38	12	3.03
Operating Revenue	375	49	63	3.80	2.64	17	56	3.08	2.38	12	3.03
Total Cost of Revenue	22	6.00	1.91	0.02	0.04	0.80	0.06	0.05	0.05	0.68	0.00
Operating Cost of Revenue	22	6.00	1.91	0.02	0.04	0.80	0.06	0.05	0.05	0.68	0.00
Total Operating Expenses	157	194	204	219	189	155	136	162	234	129	143
Selling, General & Admin Expense	43	39	47	46	41	41	36	30	26	27	24
Research & Development Expense	114	155	158	168	145	109	100	105	195	106	119
Restructuring Charge	-	-	-	5.37	3.37	-	-0.05	26	13	-	-0.01
Total Other Income / (Expense), net	23	-1.14	0.18	18	20	18	15	19	18	12	19
Interest & Investment Income	9.33	-	-	-	22	-	21	-	18	-	12
Other Income / (Expense), net	13	-17	-21	-5.45	-1.83	-2.48	-6.20	-0.11	0.24	-1.68	6.31
Income Tax Expense	42	-50	-2.23	-2.85	-3.21	-4.78	0.28	-1.51	0.18	-0.09	0.02
Basic Earnings per Share	$1.32	($0.78)	($1.06)	($1.45)	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)
Weighted Average Basic Shares Outstanding	132.73M	132.61M	133.55M	134.06M	134.29M	134.13M	135.28M	136.23M	136.65M	136.25M	137.47M
Diluted Earnings per Share	$1.30	($0.74)	($1.06)	($1.45)	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)
Weighted Average Diluted Shares Outstanding	134.96M	134.81M	133.55M	134.06M	134.29M	134.13M	135.28M	136.23M	136.65M	136.25M	137.47M
Weighted Average Basic & Diluted Shares Outstanding	133.12M	133.53M	133.98M	134.25M	134.52M	135.03M	136.06M	136.64M	137.72M	137.14M	138.24M

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	175	-130	63	329	-88	505	-607	57
Net Cash From Operating Activities	-66	-94	-130	-191	-48	1,663	-779	-446
Net Cash From Continuing Operating Activities	-66	-94	-130	-191	-48	1,663	-779	-446
Net Income / (Loss) Continuing Operations	-70	-116	-175	-299	529	516	-615	-522
Consolidated Net Income / (Loss)	-70	-116	-175	-299	529	516	-615	-522
Depreciation Expense	0.26	1.62	3.29	4.40	5.28	6.78	19	15
Amortization Expense	0.18	0.81	1.04	2.59	0.29	-8.94	-8.71	5.40
Non-Cash Adjustments To Reconcile Net Income	9.10	7.35	24	33	-61	500	131	143
Changes in Operating Assets and Liabilities, net	-6.06	12	17	68	-521	650	-306	-87
Net Cash From Investing Activities	-30	-60	-256	-9.86	-141	-1,193	165	499
Net Cash From Continuing Investing Activities	-30	-60	-256	-9.86	-141	-1,193	165	499
Purchase of Property, Plant & Equipment	-2.74	-9.94	-8.94	-6.55	-22	-68	-22	-7.30
Purchase of Investments	0.00	-123	-644	-404	-420	-1,477	-2,016	-1,235
Sale of Property, Plant & Equipment	0.00	0.03	0.00	0.00	-	0.00	0.00	3.37
Sale and/or Maturity of Investments	0.00	73	397	400	301	352	2,202	1,739
Net Cash From Financing Activities	271	25	449	529	100	35	7.48	4.39
Net Cash From Continuing Financing Activities	271	25	449	529	100	35	7.48	4.39
Repayment of Debt	0.00	0.00	3.27	-	-	-0.26	-0.29	-0.17
Issuance of Common Equity	0.00	0.00	126	530	88	32	4.28	3.76
Other Financing Activities, net	0.00	11	2.23	-0.44	13	3.34	3.48	0.79
Cash Income Taxes Paid	-	-	-	0.00	0.00	-252	2.68	0.79

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-543	-116	-25	-156	-215	-211	-81	137	-53	54	49
Net Cash From Operating Activities	118	35	-126	-389	-156	-108	-109	-78	-171	-88	-78
Net Cash From Continuing Operating Activities	118	35	-126	-389	-156	-108	-109	-78	-171	-88	-78
Net Income / (Loss) Continuing Operations	175	-102	-141	-195	-163	-116	-65	-138	-214	-105	-121
Consolidated Net Income / (Loss)	175	-102	-141	-195	-163	-116	-65	-138	-214	-105	-121
Depreciation Expense	1.55	2.35	5.64	4.75	4.59	4.48	4.52	4.26	2.90	2.89	2.87
Amortization Expense	-2.91	-8.03	-9.37	-3.00	2.31	1.35	0.24	2.64	0.35	2.17	4.09
Non-Cash Adjustments To Reconcile Net Income	-1.06	28	7.97	57	31	35	33	56	21	32	9.83
Changes in Operating Assets and Liabilities, net	-55	114	11	-253	-30	-33	-82	-2.54	18	-20	26
Net Cash From Investing Activities	-663	-153	98	230	-59	-105	28	212	119	141	127
Net Cash From Continuing Investing Activities	-663	-153	98	230	-59	-105	28	212	119	141	127
Purchase of Property, Plant & Equipment	-19	-13	-6.87	-9.46	-3.71	-1.54	-1.87	-0.67	-2.36	-2.41	-1.63
Purchase of Investments	-728	-407	-385	-310	-503	-819	-563	-271	-240	-161	-174
Sale of Property, Plant & Equipment	0.01	-0.02	0.00	-	-	-	0.53	0.38	0.01	2.46	0.28
Sale and/or Maturity of Investments	85	267	489	550	448	716	593	483	362	301	302
Net Cash From Financing Activities	1.99	2.01	2.34	3.18	0.28	1.68	0.15	2.94	0.03	1.26	0.60
Net Cash From Continuing Financing Activities	1.99	2.01	2.34	3.18	0.28	1.68	0.15	2.94	0.03	1.26	0.60
Other Financing Activities, net	1.99	1.12	2.24	0.67	0.28	0.29	0.15	0.34	0.03	0.27	0.60

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	192	512	919	1,954	2,802	1,919	1,399
Total Current Assets	118	403	772	1,563	2,519	1,588	1,042
Cash & Equivalents	48	109	437	348	849	242	223
Restricted Cash	11	6.18	7.99	8.59	13	13	89
Short-Term Investments	51	274	300	360	1,553	1,281	682
Prepaid Expenses	8.58	13	28	73	104	53	48
Plant, Property, & Equipment, net	12	16	18	43	106	96	63
Total Noncurrent Assets	62	93	128	349	177	235	293
Long-Term Investments	0.00	24	0.00	201	24	105	190
Goodwill	17	17	17	17	17	17	17
Intangible Assets	37	36	34	33	33	23	8.12
Other Noncurrent Operating Assets	6.67	8.55	71	90	97	84	72
Other Noncurrent Nonoperating Assets	1.00	7.30	6.92	7.01	6.66	6.45	6.36
Total Liabilities & Shareholders' Equity	192	512	919	1,954	2,802	1,919	1,399
Total Liabilities	62	88	202	522	724	329	248
Total Current Liabilities	40	59	99	341	511	175	120
Short-Term Debt	0.00	8.20	11	0.00	-	0.00	16
Accounts Payable	6.47	5.88	5.08	6.52	6.42	6.33	5.08
Accrued Expenses	15	26	77	237	489	104	86
Current Deferred Revenue	8.76	6.18	6.45	98	16	65	13
Total Noncurrent Liabilities	22	29	103	181	213	153	129
Other Noncurrent Operating Liabilities	11	13	96	159	160	153	129
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-179	424	717	1,432	2,078	1,590	1,150
Total Preferred & Common Equity	-179	424	717	1,432	2,078	1,590	1,150
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-179	424	717	1,432	2,078	1,590	1,150
Common Stock	15	793	1,385	1,572	1,710	1,829	1,912
Retained Earnings	-194	-369	-667	-139	377	-238	-760
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.60	-1.28	-1.10	-9.12	-0.82	-1.72

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	2,619	2,696	2,666	2,244	2,045	1,794	1,670	1,498	1,308
Total Current Assets	2,288	2,414	2,359	1,946	1,769	1,213	1,206	1,047	932
Cash & Equivalents	1,505	964	825	667	452	161	297	168	274
Restricted Cash	13	13	11	13	13	13	14	90	88
Short-Term Investments	691	1,360	1,425	1,180	1,244	989	854	746	528
Prepaid Expenses	72	54	98	86	59	50	41	43	42
Plant, Property, & Equipment, net	85	100	104	104	99	92	66	65	62
Total Noncurrent Assets	246	182	204	193	176	488	398	386	314
Long-Term Investments	98	34	49	52	40	360	280	271	218
Goodwill	17	17	17	17	17	17	17	17	17
Intangible Assets	33	33	33	26	25	22	19	19	8.07
Other Noncurrent Operating Assets	90	91	98	92	87	83	76	72	64
Other Noncurrent Nonoperating Assets	8.35	7.28	6.74	6.74	7.06	6.43	6.37	6.38	6.27
Total Liabilities & Shareholders' Equity	2,619	2,696	2,666	2,244	2,045	1,794	1,670	1,498	1,308
Total Liabilities	667	546	695	434	370	247	236	258	264
Total Current Liabilities	478	308	485	226	165	94	96	117	137
Short-Term Debt	-	-	-	-	-	-	-	-	18
Accounts Payable	11	2.72	12	12	3.63	7.11	4.39	7.31	3.73
Accrued Expenses	354	283	456	198	146	72	75	95	104
Current Deferred Revenue	113	23	17	16	15	15	17	15	12
Total Noncurrent Liabilities	189	238	210	208	205	153	139	140	127
Other Noncurrent Operating Liabilities	166	165	153	155	152	151	139	140	127
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,952	2,150	1,971	1,810	1,675	1,547	1,434	1,241	1,044
Total Preferred & Common Equity	1,952	2,150	1,971	1,810	1,675	1,547	1,434	1,241	1,044
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,952	2,150	1,971	1,810	1,675	1,547	1,434	1,241	1,044
Common Stock	1,656	1,683	1,738	1,772	1,799	1,853	1,878	1,895	1,927
Retained Earnings	304	479	236	42	-122	-303	-441	-655	-881
Accumulated Other Comprehensive Income / (Loss)	-7.55	-12	-3.22	-2.90	-1.90	-2.40	-2.88	1.13	-1.98

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	293.94%	-24.16%	843.86%	1,334.39%	47.51%	-94.67%	-13.90%
EBITDA Growth	0.00%	-43.83%	-53.42%	-64.78%	288.46%	30.47%	-197.29%	18.38%
EBIT Growth	0.00%	-46.05%	-53.94%	-64.69%	282.24%	32.19%	-198.48%	16.82%
NOPAT Growth	0.00%	-45.64%	-49.95%	-66.86%	294.58%	40.84%	-184.08%	14.20%
Net Income Growth	0.00%	-65.90%	-50.74%	-70.98%	276.98%	-2.41%	-219.25%	15.14%
EPS Growth	0.00%	53.41%	61.90%	56.42%	257.77%	-3.28%	-219.84%	16.56%
Operating Cash Flow Growth	0.00%	-41.75%	-37.77%	-47.29%	75.08%	3,595.04%	-146.82%	42.69%
Free Cash Flow Firm Growth	0.00%	0.00%	-10.48%	-50.45%	26.71%	1,241.11%	-154.66%	43.80%
Invested Capital Growth	0.00%	0.00%	-47.37%	-322.41%	2,183.45%	-172.49%	84.44%	56.85%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	1.00%	285.18%	-32.08%	-27.46%	-5.61%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-15.57%	674.37%	-49.91%	5.10%	3.67%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-15.28%	639.22%	-49.56%	3.55%	3.67%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-17.69%	322.77%	-53.46%	1.65%	3.59%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-16.31%	616.60%	-54.86%	-2.39%	2.13%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-162.44%	540.00%	-55.31%	-2.68%	2.30%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-7.80%	-29.21%	65.35%	1.68%	-22.50%	4.35%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	29.04%	-1.61%	-20.18%	4.91%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-439.99%	6,607.20%	-46.37%	29.72%	40.16%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	93.99%	90.94%	96.79%	98.86%
EBITDA Margin	-2,990.47%	-1,091.83%	-2,208.65%	-385.58%	50.66%	44.81%	-817.40%	-774.82%
Operating Margin	-3,009.49%	-1,112.60%	-2,199.72%	-388.88%	38.41%	51.56%	-794.04%	-791.27%
EBIT Margin	-3,006.43%	-1,114.59%	-2,262.27%	-394.73%	50.15%	44.94%	-829.87%	-801.72%
Profit (Net Income) Margin	-2,579.47%	-1,086.28%	-2,158.98%	-391.09%	48.25%	31.92%	-713.76%	-703.40%
Tax Burden Percent	86.48%	99.59%	100.09%	100.02%	96.14%	68.39%	97.92%	99.78%
Interest Burden Percent	99.22%	97.86%	95.35%	99.06%	100.08%	103.87%	87.84%	87.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	3.86%	31.61%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-799.77%	-785.73%	0.00%	167.71%	817.53%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-739.69%	-766.54%	0.00%	152.82%	820.73%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	621.43%	722.66%	0.00%	-118.51%	-788.14%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-178.34%	-63.07%	-52.36%	49.20%	29.39%	-33.54%	-38.09%
Cash Return on Invested Capital (CROIC)	0.00%	-999.77%	-723.66%	0.00%	-24.97%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-62.06%	-52.02%	-42.14%	38.24%	30.54%	-30.30%	-35.86%
Return on Assets (ROA)	0.00%	-60.48%	-49.65%	-41.75%	36.80%	21.69%	-26.06%	-31.46%
Return on Common Equity (ROCE)	0.00%	245.88%	-27.87%	-52.36%	49.20%	29.39%	-33.54%	-38.09%
Return on Equity Simple (ROE_SIMPLE)	0.00%	64.68%	-41.20%	-41.66%	36.92%	24.82%	-38.68%	-45.37%
Net Operating Profit after Tax (NOPAT)	-57	-83	-125	-208	405	570	-479	-411
NOPAT Margin	-2,106.64%	-778.82%	-1,539.80%	-272.22%	36.93%	35.26%	-555.83%	-553.89%
Net Nonoperating Expense Percent (NNEP)	0.00%	-60.08%	-19.19%	-15.73%	14.89%	-3.20%	-6.65%	-7.86%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	27.42%	-30.12%	-35.24%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	6.01%	9.06%	3.21%	1.14%
SG&A Expenses to Revenue	801.07%	273.07%	464.69%	92.89%	14.68%	10.01%	202.41%	160.41%
R&D to Revenue	2,308.42%	939.53%	1,835.03%	395.99%	40.90%	29.38%	672.69%	682.57%
Operating Expenses to Revenue	3,109.49%	1,212.60%	2,299.72%	488.88%	55.58%	39.39%	890.83%	890.14%
Earnings before Interest and Taxes (EBIT)	-81	-119	-183	-301	549	726	-715	-595
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-81	-116	-179	-294	555	724	-704	-575
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.25	4.76	3.83	1.62	0.85	0.88
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.71	5.12	3.97	1.66	0.87	0.90
Price to Revenue (P/Rev)	52.75	13.39	170.46	44.67	5.00	2.09	15.70	13.62
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	10.37	6.53	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	9.65%	15.31%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	16.50	89.03	0.00	9.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	32.13	120.32	35.06	4.16	0.58	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	8.22	1.29	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	8.30	1.28	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	11.28	1.63	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.02	0.01	0.00	0.00	0.00	0.01
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.84	-0.94	-1.01	-0.78	-0.96	-1.12	-1.03
Leverage Ratio	0.00	1.47	1.27	1.25	1.34	1.36	1.29	1.21
Compound Leverage Factor	0.00	1.44	1.21	1.24	1.34	1.41	1.13	1.06
Debt to Total Capital	0.00%	0.00%	1.90%	1.46%	0.00%	0.00%	0.00%	1.38%
Short-Term Debt to Total Capital	0.00%	0.00%	1.90%	1.46%	0.00%	0.00%	0.00%	1.38%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	237.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-137.87%	98.10%	98.54%	100.00%	100.00%	100.00%	98.62%
Debt to EBITDA	0.00	0.00	-0.05	-0.04	0.00	0.00	0.00	-0.03
Net Debt to EBITDA	0.00	0.00	2.27	2.49	0.00	0.00	0.00	2.03
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-0.07	-0.05	0.00	0.00	0.00	-0.04
Net Debt to NOPAT	0.00	0.00	3.26	3.53	0.00	0.00	0.00	2.84
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.53	8.02	9.00	8.43	5.27	1.99	1.12
Noncontrolling Interest Sharing Ratio	0.00%	237.87%	55.81%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	2.95	6.81	7.80	4.58	4.93	9.05	8.71
Quick Ratio	0.00	2.47	6.48	7.44	4.34	4.70	8.68	7.57
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-104	-115	-173	-127	1,444	-789	-444
Operating Cash Flow to CapEx	-2,420.90%	-949.51%	-1,450.02%	-2,915.57%	-218.13%	2,445.74%	-3,610.00%	-11,360.45%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.06	0.02	0.11	0.76	0.68	0.04	0.04
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.87	0.57	4.46	36.05	21.77	0.85	0.93
Accounts Payable Turnover	0.00	0.00	0.00	0.00	11.36	22.61	0.43	0.15
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	32.14	16.14	841.94	2,465.37
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-32.14	-16.14	-841.94	-2,465.37
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	21	11	-24	507	-367	-57	-25
Invested Capital Turnover	0.00	1.03	0.51	-11.41	4.54	23.19	-0.41	-1.81
Increase / (Decrease) in Invested Capital	0.00	21	-9.84	-35	531	-874	310	32
Enterprise Value (EV)	0.00	343	974	2,677	4,562	931	-288	-158
Market Capitalization	143	143	1,379	3,411	5,480	3,369	1,353	1,011
Book Value per Share	$0.00	($23.37)	$3.87	$5.63	$10.94	$15.61	$11.82	$8.35
Tangible Book Value per Share	$0.00	($30.40)	$3.39	$5.23	$10.56	$15.24	$11.53	$8.17
Total Capital	0.00	130	432	727	1,432	2,078	1,590	1,166
Total Debt	0.00	0.00	8.20	11	0.00	0.00	0.00	16
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-109	-406	-734	-918	-2,439	-1,641	-1,169
Capital Expenditures (CapEx)	2.74	9.91	8.94	6.55	22	68	22	3.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-31	-38	-61	505	-407	-123	-56
Debt-free Net Working Capital (DFNWC)	0.00	78	352	684	1,222	2,008	1,413	939
Net Working Capital (NWC)	0.00	78	344	673	1,222	2,008	1,413	923
Net Nonoperating Expense (NNE)	13	33	50	91	-124	54	136	111
Net Nonoperating Obligations (NNO)	0.00	-109	-413	-741	-925	-2,445	-1,647	-1,175
Total Depreciation and Amortization (D&A)	0.43	2.43	4.34	6.99	5.57	-2.16	11	20
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-293.67%	-465.06%	-79.81%	46.09%	-25.17%	-142.56%	-75.30%
Debt-free Net Working Capital to Revenue	0.00%	729.99%	4,350.38%	895.53%	111.52%	124.28%	1,639.38%	1,265.22%
Net Working Capital to Revenue	0.00%	729.99%	4,249.03%	881.65%	111.52%	124.28%	1,639.38%	1,243.58%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($5.76)	($2.51)	$4.07	$3.89	($4.59)	($3.83)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	109.80M	127.84M	129.88M	132.61M	134.13M	136.25M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($5.76)	($2.51)	$3.96	$3.83	($4.59)	($3.83)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	109.80M	127.84M	133.44M	134.81M	134.13M	136.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($5.76)	($2.51)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	30.35M	119.16M	132.30M	133.53M	135.03M	137.14M
Normalized Net Operating Profit after Tax (NOPAT)	-57	-83	-125	-208	405	570	-470	-387
Normalized NOPAT Margin	-2,106.64%	-778.82%	-1,539.80%	-272.22%	36.93%	35.26%	-544.82%	-520.88%
Pre Tax Income Margin	-2,982.87%	-1,090.78%	-2,157.08%	-391.02%	50.19%	46.68%	-728.93%	-704.95%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	261.49%	-93.92%	-94.89%	109.35%	-99.30%	-66.03%	-10.45%	-19.02%	-9.81%	-26.29%	-94.62%
EBITDA Growth	85.49%	-131.67%	-118.20%	6.32%	-187.74%	21.80%	51.54%	30.63%	-25.41%	16.13%	-54.89%
EBIT Growth	88.17%	-130.75%	-117.85%	6.48%	-190.48%	15.68%	47.55%	28.06%	-22.54%	16.02%	-54.42%
NOPAT Growth	394.94%	-119.15%	-117.60%	4.46%	-183.27%	7.63%	44.14%	26.28%	-23.87%	15.73%	-74.26%
Net Income Growth	58.76%	-119.34%	-127.18%	-154.63%	-193.21%	-14.14%	53.69%	28.95%	-30.78%	9.82%	-85.31%
EPS Growth	58.54%	-118.50%	-127.53%	-150.00%	-193.85%	-16.22%	54.72%	29.66%	-27.87%	10.47%	-83.33%
Operating Cash Flow Growth	211.42%	356.48%	-122.87%	-140.54%	-232.17%	-407.26%	13.03%	80.00%	-10.04%	18.80%	28.59%
Free Cash Flow Firm Growth	901.25%	3,924.14%	-50.55%	-618.49%	-175.06%	-153.01%	-271.00%	49.78%	32.73%	71.90%	93.65%
Invested Capital Growth	-3,122.79%	-172.49%	0.00%	69.82%	67.59%	84.44%	105.23%	83.84%	49.32%	56.85%	-392.21%
Revenue Q/Q Growth	1,021.90%	-86.81%	27.42%	-93.97%	-30.50%	536.11%	235.83%	-94.55%	-22.60%	419.92%	-75.50%
EBITDA Q/Q Growth	188.60%	-183.80%	3.03%	-30.12%	17.01%	25.32%	39.90%	-86.24%	-50.04%	50.06%	-10.99%
EBIT Q/Q Growth	188.33%	-180.52%	1.98%	-34.13%	14.54%	24.96%	39.02%	-83.97%	-45.57%	48.57%	-12.13%
NOPAT Q/Q Growth	199.57%	-167.11%	4.74%	-50.09%	13.22%	25.55%	42.39%	-98.09%	-45.81%	49.35%	-19.12%
Net Income Q/Q Growth	329.19%	-157.96%	-38.73%	-38.18%	16.10%	29.03%	43.71%	-111.99%	-54.44%	51.06%	-15.66%
EPS Q/Q Growth	324.14%	-156.92%	-43.24%	-36.79%	15.86%	29.51%	44.19%	-112.50%	-52.94%	50.64%	-14.29%
Operating Cash Flow Q/Q Growth	-87.72%	-70.21%	-458.09%	-209.46%	59.97%	30.74%	-1.36%	28.84%	-120.28%	48.89%	10.86%
Free Cash Flow Firm Q/Q Growth	413.66%	92.10%	-68.02%	-264.33%	25.64%	-35.68%	-3.15%	51.74%	0.40%	43.32%	76.71%
Invested Capital Q/Q Growth	30.82%	-46.37%	5.77%	68.37%	25.71%	29.72%	131.67%	-197.75%	-132.91%	40.16%	-114.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	94.06%	87.86%	96.97%	99.42%	98.56%	95.25%	99.90%	98.31%	97.90%	94.47%	100.00%
EBITDA Margin	55.27%	-351.11%	-267.20%	-5,764.87%	-6,883.74%	-808.14%	-144.61%	-4,937.85%	-9,572.14%	-919.46%	-4,164.94%
Operating Margin	52.05%	-304.60%	-227.73%	-5,667.26%	-7,075.86%	-828.12%	-142.05%	-5,158.70%	-9,718.66%	-946.74%	-4,602.47%
EBIT Margin	55.64%	-339.63%	-261.28%	-5,810.88%	-7,145.02%	-842.87%	-153.05%	-5,162.15%	-9,708.70%	-960.30%	-4,394.36%
Profit (Net Income) Margin	46.81%	-205.63%	-223.89%	-5,129.71%	-6,192.23%	-690.85%	-115.79%	-4,500.10%	-8,979.71%	-845.23%	-3,989.61%
Tax Burden Percent	80.52%	67.00%	98.44%	98.56%	98.07%	96.04%	100.42%	98.92%	100.08%	99.92%	100.01%
Interest Burden Percent	104.48%	90.36%	87.05%	89.57%	88.37%	85.34%	75.33%	88.13%	92.41%	88.09%	90.78%
Effective Tax Rate	19.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-4,943.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-4,943.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	4,747.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	75.52%	-196.10%	-7.29%	-13.93%	-31.41%	-33.54%	-30.67%	-29.78%	-36.58%	-38.09%	-44.59%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,412.76%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	67.78%	-230.75%	-43.74%	-1,172.77%	-358.10%	-30.77%	-5.46%	-208.09%	-430.84%	-42.95%	-59.11%
Return on Assets (ROA)	57.02%	-139.71%	-37.48%	-1,035.30%	-310.35%	-25.22%	-4.13%	-181.40%	-398.49%	-37.81%	-53.67%
Return on Common Equity (ROCE)	75.52%	-196.10%	-7.29%	-13.93%	-31.41%	-33.54%	-30.67%	-29.78%	-36.58%	-38.09%	-44.59%
Return on Equity Simple (ROE_SIMPLE)	53.15%	0.00%	-7.29%	-14.47%	-35.86%	0.00%	-34.86%	-33.69%	-42.99%	0.00%	-55.34%
Net Operating Profit after Tax (NOPAT)	157	-105	-100	-151	-131	-97	-56	-111	-162	-82	-98
NOPAT Margin	41.91%	-213.22%	-159.41%	-3,967.08%	-4,953.10%	-579.68%	-99.43%	-3,611.09%	-6,803.06%	-662.72%	-3,221.73%
Net Nonoperating Expense Percent (NNEP)	1.12%	0.22%	-3.50%	-2.09%	-1.57%	-0.91%	-0.48%	-1.62%	-3.41%	-1.60%	-1.77%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.07%	-	-	-	-6.12%	-	-	-	-7.03%	-9.20%
Cost of Revenue to Revenue	5.94%	12.14%	3.03%	0.58%	1.44%	4.75%	0.10%	1.69%	2.10%	5.53%	0.00%
SG&A Expenses to Revenue	11.53%	78.41%	74.30%	1,198.63%	1,551.08%	245.54%	64.34%	984.23%	1,081.68%	216.17%	789.71%
R&D to Revenue	30.48%	314.05%	250.40%	4,426.73%	5,495.57%	649.11%	177.60%	3,418.31%	8,200.76%	857.31%	3,913.09%
Operating Expenses to Revenue	42.01%	392.46%	324.70%	5,766.68%	7,174.42%	923.36%	241.94%	5,257.01%	9,816.55%	1,041.22%	4,702.47%
Earnings before Interest and Taxes (EBIT)	208	-168	-164	-221	-189	-141	-86	-159	-231	-119	-133
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	207	-173	-168	-219	-182	-136	-82	-152	-228	-114	-126
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.19	1.62	1.58	1.82	0.75	0.85	0.88	0.84	0.82	0.88	0.85
Price to Tangible Book Value (P/TBV)	1.22	1.66	1.62	1.86	0.77	0.87	0.90	0.87	0.85	0.90	0.87
Price to Revenue (P/Rev)	1.07	2.09	6.96	6.70	10.59	15.70	17.12	15.35	13.02	13.62	42.60
Price to Earnings (P/E)	2.24	6.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	44.68%	15.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.08	0.58	1.79	2.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.13	1.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.13	1.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.15	1.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.11	0.56	0.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.13	0.64	6.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.09	-0.96	-1.18	-1.13	-1.09	-1.12	-1.09	-1.04	-1.04	-1.03	-1.01
Leverage Ratio	1.29	1.36	1.35	1.29	1.24	1.29	1.27	1.21	1.22	1.21	1.20
Compound Leverage Factor	1.35	1.22	1.18	1.16	1.10	1.10	0.96	1.06	1.12	1.07	1.09
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.38%	1.65%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.38%	1.65%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	98.62%	98.35%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.03	-0.03
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.03	1.76
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.04	-0.04
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.84	2.41
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.13	4.22	3.61	5.39	2.65	2.98	3.71	3.24	2.06	2.25	1.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.83	4.93	4.86	8.63	10.72	9.05	12.90	12.51	8.94	8.71	6.79
Quick Ratio	7.54	4.70	4.64	8.19	10.28	8.68	12.22	11.94	7.81	7.57	5.84
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	400	769	246	-404	-300	-407	-420	-203	-202	-115	-27
Operating Cash Flow to CapEx	621.13%	278.87%	-1,831.69%	-4,115.97%	-4,195.72%	-7,031.07%	-8,169.53%	-27,124.39%	-7,293.92%	0.00%	-5,794.96%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.22	0.68	0.17	0.20	0.05	0.04	0.04	0.04	0.04	0.04	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	37.52	21.77	4.30	5.19	1.19	0.85	0.81	0.93	0.96	0.93	0.27
Accounts Payable Turnover	56.78	22.61	4.78	2.63	2.51	0.43	0.10	0.11	0.18	0.15	0.15
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	6.43	16.14	76.35	138.97	145.51	841.94	3,833.69	3,228.15	2,080.39	2,465.37	2,516.69
Cash Conversion Cycle (CCC)	-6.43	-16.14	-76.35	-138.97	-145.51	-841.94	-3,833.69	-3,228.15	-2,080.39	-2,465.37	-2,516.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-251	-367	-346	-109	-81	-57	18	-18	-41	-25	-53
Invested Capital Turnover	-18.39	23.19	-2.58	-2.08	-0.72	-0.41	-0.49	-1.24	-1.28	-1.81	-1.20
Increase / (Decrease) in Invested Capital	-243	-874	-346	253	170	310	364	92	40	32	-71
Enterprise Value (EV)	187	931	797	1,373	-491	-288	-160	-234	-252	-158	-202
Market Capitalization	2,557	3,369	3,107	3,286	1,258	1,353	1,363	1,211	1,023	1,011	889
Book Value per Share	$16.21	$15.61	$14.76	$13.51	$12.48	$11.82	$11.44	$10.54	$9.08	$8.35	$7.61
Tangible Book Value per Share	$15.83	$15.24	$14.39	$13.19	$12.16	$11.53	$11.15	$10.27	$8.82	$8.17	$7.43
Total Capital	2,150	2,078	1,971	1,810	1,675	1,590	1,547	1,434	1,241	1,166	1,061
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	16	18
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2,371	-2,439	-2,310	-1,913	-1,749	-1,641	-1,523	-1,445	-1,276	-1,169	-1,090
Capital Expenditures (CapEx)	19	13	6.87	9.46	3.71	1.54	1.34	0.29	2.35	-0.05	1.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-231	-407	-388	-140	-106	-123	-44	-56	-74	-56	-77
Debt-free Net Working Capital (DFNWC)	2,105	2,008	1,873	1,721	1,604	1,413	1,119	1,109	930	939	812
Net Working Capital (NWC)	2,105	2,008	1,873	1,721	1,604	1,413	1,119	1,109	930	923	795
Net Nonoperating Expense (NNE)	-18	-3.75	41	44	33	19	9.22	27	52	23	23
Net Nonoperating Obligations (NNO)	-2,401	-2,445	-2,317	-1,920	-1,756	-1,647	-1,529	-1,451	-1,282	-1,175	-1,097
Total Depreciation and Amortization (D&A)	-1.37	-5.68	-3.73	1.75	6.90	5.83	4.76	6.90	3.25	5.05	6.96
Debt-free, Cash-free Net Working Capital to Revenue	-9.72%	-25.17%	-86.87%	-28.51%	-88.90%	-142.56%	-55.36%	-70.59%	-94.22%	-75.30%	-370.99%
Debt-free Net Working Capital to Revenue	88.49%	124.28%	419.76%	350.65%	1,350.24%	1,639.38%	1,405.83%	1,406.40%	1,182.93%	1,265.22%	3,894.45%
Net Working Capital to Revenue	88.49%	124.28%	419.76%	350.65%	1,350.24%	1,639.38%	1,405.83%	1,406.40%	1,182.93%	1,243.58%	3,810.56%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.32	($0.78)	($1.06)	($1.45)	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)
Adjusted Weighted Average Basic Shares Outstanding	132.73M	132.61M	133.55M	134.06M	134.29M	134.13M	135.28M	136.23M	136.65M	136.25M	137.47M
Adjusted Diluted Earnings per Share	$1.30	($0.74)	($1.06)	($1.45)	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)
Adjusted Weighted Average Diluted Shares Outstanding	134.96M	134.81M	133.55M	134.06M	134.29M	134.13M	135.28M	136.23M	136.65M	136.25M	137.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	133.12M	133.53M	133.98M	134.25M	134.52M	135.03M	136.06M	136.64M	137.72M	137.14M	138.24M
Normalized Net Operating Profit after Tax (NOPAT)	157	-105	-100	-147	-128	-97	-56	-93	-153	-82	-98
Normalized NOPAT Margin	41.91%	-213.22%	-159.41%	-3,868.16%	-4,863.66%	-579.68%	-99.43%	-3,012.96%	-6,429.18%	-662.72%	-3,221.96%
Pre Tax Income Margin	58.13%	-306.90%	-227.44%	-5,204.71%	-6,313.98%	-719.35%	-115.30%	-4,549.27%	-8,972.27%	-845.93%	-3,989.08%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	-0.04%	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-0.04%	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Vir Biotechnology’s Q1 2025 results show continued investment in R&D and stable operational funding, but revenue remains modest and losses have widened. The company generated $3.03 million in total revenue, incurred operating expenses of $142.6 million, and reported a net loss of $120.9 million (EPS: -$0.88). Strong liquidity and low leverage underpin the balance sheet, but free cash flow turned negative for the quarter.

Strong liquidity with $273.6 million in cash & equivalents and $528.1 million in short-term investments, providing runway for operations.
Net cash increased by $49.3 million in Q1 2025 due to positive investing and financing cash flows.
Low leverage: debt-to-equity of 0.016 and net debt of –$1.09 billion signal a conservative capital structure.
Current ratio of 6.79 and quick ratio of 5.84 reflect ample working capital coverage of liabilities.
Price-to-book ratio of 0.85 suggests the stock trades below book value, potentially attractive for value investors.
Revenue held at $3.03 million in Q1 2025, consistent with the run-rate following Q1 2024’s one-time spike.
R&D expense climbed to $118.6 million in Q1 2025, underscoring continued investment in the pipeline.
Net loss widened to $120.9 million (–46% operating margin) from $65.3 million a year earlier, with EPS declining to –$0.88.
Free cash flow to the firm was –$26.7 million in Q1 2025, reversing a positive $245.8 million in Q1 2024.
High price-to-revenue multiple (~42.6×) indicates a lofty valuation against modest quarterly sales.

06/19/25 12:00 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Vir Biotechnology's Financials

When does Vir Biotechnology's financial year end?

According to the most recent income statement we have on file, Vir Biotechnology's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Vir Biotechnology's net income changed over the last 7 years?

Vir Biotechnology's net income appears to be on an upward trend, with a most recent value of -$521.96 million in 2024, rising from -$69.85 million in 2017. The previous period was -$615.12 million in 2023. See where experts think Vir Biotechnology is headed by visiting Vir Biotechnology's forecast page.

What is Vir Biotechnology's operating income?

Vir Biotechnology's total operating income in 2024 was -$587.17 million, based on the following breakdown:

Total Gross Profit: $73.36 million
Total Operating Expenses: $660.53 million

How has Vir Biotechnology's revenue changed over the last 7 years?

Over the last 7 years, Vir Biotechnology's total revenue changed from $2.71 million in 2017 to $74.21 million in 2024, a change of 2,640.2%.

How much debt does Vir Biotechnology have?

Vir Biotechnology's total liabilities were at $248.43 million at the end of 2024, a 24.4% decrease from 2023, and a 303.1% increase since 2018.

How much cash does Vir Biotechnology have?

In the past 6 years, Vir Biotechnology's cash and equivalents has ranged from $47.60 million in 2018 to $848.63 million in 2022, and is currently $222.95 million as of their latest financial filing in 2024.

How has Vir Biotechnology's book value per share changed over the last 7 years?

Over the last 7 years, Vir Biotechnology's book value per share changed from 0.00 in 2017 to 8.35 in 2024, a change of 835.3%.

Related Companies

This page (NASDAQ:VIR) was last updated on 6/19/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Financials

Key Financial Trends

Frequently Asked Questions About Vir Biotechnology's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Financials

Annual Income Statements for Vir Biotechnology

Quarterly Income Statements for Vir Biotechnology

Annual Cash Flow Statements for Vir Biotechnology

Quarterly Cash Flow Statements for Vir Biotechnology

Annual Balance Sheets for Vir Biotechnology

Quarterly Balance Sheets for Vir Biotechnology

Annual Metrics And Ratios for Vir Biotechnology

Quarterly Metrics And Ratios for Vir Biotechnology

Key Financial Trends

Frequently Asked Questions About Vir Biotechnology's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools